AKEBIA THERAPEUTICS, INC. Proceeds from Long-Term Debt Issued
AKEBIA THERAPEUTICS, INC. (AKBA) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-08-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2023-08-28
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2022 was $0.00.
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2020 was $19.98M, a 74.28% decline from fiscal 2019.
- AKEBIA THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2019 was $77.67M.
| Period end | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K/A · filed 2023-08-28 |
| 2021-12-31 | $0.00 10-K/A · filed 2023-08-28 |
| 2020-12-31 | $19.98M 10-K/A · filed 2023-08-28 |
| 2019-12-31 | $77.67M 10-K · filed 2022-03-01 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |